Proteinuria

SAN DIEGO — Pegcetacoplan may offer a clinical strategy to stabilize kidney function and reduce proteinuria significantly for patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, data show.

The FDA granted full approval to Filspari, a daily oral, non-immunosuppressive medication, to slow kidney function decline in adults with primary IgA nephropathy, according to an industry press release.

More than half of patients with diabetes undergoing kidney biopsy had additional findings other than diabetic kidney disease, according to published data from the Cleveland Clinic Florida.

Sobi and Apellis Pharmaceuticals Inc. announced results from the phase 3 Valiant study showing the drug pegcetacoplan reduced proteinuria and stabilized eGFR compared to placebo in patients with glomerulopathy or glomerulonephritis.

Higher intake of total, animal and plant protein may be linked to lower mortality in older adults with mild or moderate chronic kidney disease, according to a cohort study.

The FDA has granted accelerated approval for Fabhalta to treat proteinuria in patients with primary IgA nephropathy, according to a press release.

Incident cardiovascular and thromboembolic events may be more closely linked to the severity of kidney disease than with glomerular disease subtype, according to results of a prospective study.

Urinary plasminogen and the ratio of measured to expected plasminogen may be independently linked to the risk of progression to end-stage kidney disease, data show.

Matrix metalloproteinase 2 may be associated with the progression of chronic kidney disease, especially in patients with low inflammation or with proteinuria, data show.

Among older adults participating in the Systolic Blood Pressure Intervention Trial, a low eGFR without albuminuria was associated with a higher mortality rate but not with increased risk of cardiovascular events, results showed.